Reuters logo
BRIEF-Chemocentryx reports Q3 revenue $9.0 million
November 7, 2017 / 9:52 PM / 17 days ago

BRIEF-Chemocentryx reports Q3 revenue $9.0 million

Nov 7 (Reuters) - Chemocentryx Inc:

* Chemocentryx reports third quarter 2017 financial results and recent highlights

* Q3 revenue $9.0 million versus I/B/E/S view $9 million

* Chemocentryx Inc - ‍expects to utilize cash and cash equivalents in range of $50 million and $55 million in 2017​

* Chemocentryx inc - ‍phase iii advocate trial of avacopan remains on track to complete enrollment in mid-2018​

* Chemocentryx Inc - ‍plan to launch registration-supporting trial for CCX140 in treatment of focal segmental glomerulosclerosis (FSGS) in Q4 2017​

* Chemocentryx Inc - qtrly loss per share $0.13​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below